MTOR and nonpapillary renal cell carcinoma: Preliminary findings from this ongoing study support the prognostic value of non-VHL mutations includingPBRM1, BAP1, SETD2, KDM5C, ATM, MTOR, andPTEN in primary ccRCC tumors as surrogates of earlier recurrence and potential selection for adjuvant immune checkpoint inhibition.